bims-rebome Biomed News
on Management of bone metastases
Issue of 2026–11–15
fifteen papers selected by
Alberto Selvanetti, Azienda Ospedaliera San Giovanni Addolorata



  1. Neurosurg Pract. 2026 Dec;7(6): e000316
       BACKGROUND AND OBJECTIVES: Spinal metastases frequently require surgical stabilization and/or decompression followed by postoperative radiotherapy (RT). Preoperative stereotactic body radiotherapy (SBRT) may reduce postoperative complications and improve local tumor control. The primary objective of this exploratory trial is to evaluate safety and preliminary efficacy of preoperative SBRT in patients with spinal metastases.
    METHODS: The Preoperative Stereotactic Radiotherapy for Spinal Metastases study is a single-center, prospective, exploratory, interventional trial that will enroll 20 patients scheduled for surgical treatment of spinal metastases at University Medical Center Göttingen. Patients will receive SBRT (1-3 fractions) performed 1 to 3 days before surgery. The primary endpoint is local tumor control at 3 months after surgery. Secondary endpoints include pain control, wound healing disturbances, quality of life, neurological function, and instrumentation failure.
    EXPECTED OUTCOMES: The study is expected to provide first prospective data on the feasibility and safety of integrating preoperative SBRT into the treatment sequence for spinal metastases. It will also generate early evidence on local tumor control, perioperative morbidity, patient-reported outcomes, and instrumentation-related outcomes.
    DISCUSSION: Preoperative Stereotactic Radiotherapy for Spinal Metastases evaluates a novel treatment sequence intended to address limitations of postoperative RT, including delayed treatment initiation and implant-related planning challenges. The rationale is supported by preoperative SBRT approaches for brain metastases, where treatment of the intact lesion before resection has been investigated to improve target definition and avoid irradiation of postoperative cavities. The study is intended to generate initial feasibility, safety, and preliminary efficacy data that may inform the design of a subsequent randomized trial comparing preoperative with postoperative RT.
    Keywords:  Pain management; Preoperative radiotherapy; Quality of life; Spinal metastases; Stereotactic body radiotherapy; Surgical intervention; Tumor control
    DOI:  https://doi.org/10.1227/neuprac.0000000000000316
  2. Front Endocrinol (Lausanne). 2026 ;17 1906789
       Background: Bone metastases (BM) are an increasingly recognized manifestation of advanced neuroendocrine tumors (NETs), but their prevalence and association with survival in NETs of unknown primary (CUP NET) remain insufficiently characterized. We assessed the prevalence of BM and their association with overall survival (OS) in patients with metastatic pancreatic NETs (PanNETs), small intestinal NETs (siNETs), and CUP NETs.
    Methods: We conducted a retrospective analysis of 642 patients with histologically confirmed metastatic well-differentiated NETs who were treated at the European Neuroendocrine Tumour Society (ENETS) Center Essen between 2009 and 2023 using somatostatin-receptor (SSTR)- based hybrid imaging with 68Ga-DOTATOC PET/CT. The patients included 171 with PanNETs, 305 with siNETs, and 166 with CUP NETs. The primary outcome was OS, defined as the time from date of initial NET diagnosis to death from any cause. Secondary outcomes included BM prevalence, entity-specific survival according to BM status, BM morphology and timing, and skeletal-related events.
    Results: BM were detected in 238 patients (37.1%) and were most frequent in CUP NETs (42.8%), followed by PanNETs (36.3%) and siNETs (34.4%). Median OS in the overall cohort was 77 months (95% confidence interval [CI], 64-89) in patients with BM and 141 months (95% CI, 119-186) in metastatic patients without BM (log-rank p < 0.001). In CUP NETs, median OS was 30 months in patients with BM and 66 months in metastatic patients without BM (log-rank p = 0.021). In multivariable Cox regression adjusted for age, sex, tumor grade, functioning status, and tumor entity, BM remained associated with shorter OS (hazard ratio [HR], 1.45; 95% CI, 1.13-1.85; p = 0.0034). In an entity-stratified model BM remained associated with OS (HR, 1.43; 95% CI, 1.09-1.89; p = 0.011). In the CUP NET subgroup, the adjusted HR associated with BM was 1.83 (95% CI, 1.17-2.85; p = 0.008).
    Conclusion: BM were common in patients with metastatic NETs and are particularly prevalent and clinically relevant in CUP NET.
    Keywords:  bone metastases; cancer of unknown primary; neuroendocrine tumors (NET); overall survival; pancreatic neuroendocrine tumor (PanNET); small intestinal neuroendocrine tumors; somatostatin receptor imaging
    DOI:  https://doi.org/10.3389/fendo.2026.1906789
  3. Cancers (Basel). 2026 Oct 30. pii: 3500. [Epub ahead of print]18(21):
      Background/Objectives: Bone metastases arise within a specialized microenvironment in which tumor cells interact with skeletal, stromal, vascular, immune, and hematopoietic compartments. Radiotherapy therefore affects not only metastatic tumor cells but also the surrounding bone and marrow niches. This review examines radiation-induced remodeling of the bone metastatic and bone marrow microenvironments across external-beam radiotherapy (EBRT) and radiopharmaceutical therapy (RPT). Methods: We performed a narrative synthesis of experimental and clinical studies addressing cellular radiosensitivity, skeletal and stromal remodeling, hematopoietic injury, vascular and immune responses, oxidative and metabolic stress, and spatial and temporal patterns of radiation delivery. Emerging transcriptomic, proteomic, metabolomic, lipidomic, single-cell, and spatial approaches were also considered. Results: EBRT and RPT produce overlapping but biologically distinct perturbations because of differences in dose rate, exposure duration, particle range, target localization, microscopic energy deposition, and spatial dose heterogeneity. These differences can influence tumor control, resistance, bone remodeling, and marrow toxicity through effects on osteoblasts, osteoclasts, stromal and vascular cells, immune populations, and HSPCs. These issues are particularly relevant to metastatic castration-resistant prostate cancers, in which bone seeking and tumor targeting radiopharmaceuticals differentially irradiate cellular compartments within the same skeletal environment. Conclusions: Bone metastases should be viewed as part of a dynamic bone-tumor-marrow microenvironment. Integrating radiation biology, spatial dosimetry, and multi-omics may support more individualized treatment strategies that maximize tumor control while limiting skeletal and hematologic injury.
    Keywords:  bone marrow microenvironment; bone metastasis; bone remodeling; hematopoietic stem cells; lipidomics; metabolomics; multi-omics; oxidative stress; radiopharmaceutical therapy; radiotherapy
    DOI:  https://doi.org/10.3390/cancers18213500
  4. Hand Clin. 2027 Feb;pii: S0749-0712(26)00062-4. [Epub ahead of print]43(1): 107-112
      Metastatic tumors to the hand and arm (acrometastases) are rare, representing 0.1% of all bony metastases and typically signal advanced malignancy with poor prognosis. The most common primary sources are lung, kidney, colon, and breast cancers with frequent involvement of the distal phalanges. Diagnosis can be challenging due to symptom overlap with infection, trauma, or arthritis, which can delay diagnosis and treatment. These metastatic lesions can impair quality of life and hand function. Optimal management requires a multidisciplinary approach focused on function preservation and palliation. Treatment is tailored to individual patient needs utilizing nonsurgical modalities and surgical options.
    Keywords:  Acrometastases; Arm tumors; Hand tumors; Metastasis; Metastatic tumor
    DOI:  https://doi.org/10.1016/j.hcl.2026.08.011
  5. Cancers (Basel). 2026 Oct 22. pii: 3424. [Epub ahead of print]18(21):
      Literature evaluating the effectiveness of Enhanced Recovery After Surgery (ERAS) pathways in orthopaedic oncology, particularly in bone and soft tissue sarcomas, is varied and has not been synthesized to understand the current state of evidence. However, substantial efforts have been made to evaluate ERAS in other orthopaedics procedures, particularly in hip and knee arthroplasty. This study aims to summarize the breadth and depth of literature on ERAS pathways in orthopaedic oncology to identify critical gaps and guide future research directions given the potential benefits in this complex population. The Arksey and O'Malley framework in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) was used to generate a search strategy, define eligibility, and select studies from a comprehensive literature search. Of the nine included studies, data were extracted and analyzed using descriptive analytics. The available literature was heterogeneous; it predominantly comprised retrospective studies, concentrated on spine and spinopelvic oncology, ERAS components included, and reported outcomes (although length of stay was assessed in all included studies). Comparatively little evidence was identified in non-spine sarcoma, and no included study specifically evaluated appendicular metastatic bone disease. These findings highlight the need for prospective disease- and surgery-specific ERAS implementation studies using standardized pathway definitions, adherence measures, and perioperative outcomes.
    Keywords:  ERAS; enhanced recovery; fast-track; metastatic bone disease; sarcoma
    DOI:  https://doi.org/10.3390/cancers18213424
  6. World Neurosurg. 2026 Nov 11. pii: S1878-8750(26)00719-9. [Epub ahead of print] 125503
       PURPOSE: Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancers, and spinal metastasis has only occasionally been reported. Knowledge regarding its management and outcomes remains limited. We report the clinical presentation, surgical management, and outcomes of three cases and provide a focused review of reported vertebral involvement treated with spine-directed intervention.
    METHODS: Between January 2015 and December 2024, three patients with spinal metastases from MBC underwent surgery at our center. Clinical characteristics, treatment strategies, and outcomes were retrospectively reviewed. A focused search of PubMed and Google Scholar was performed, and three reported cases meeting the criteria for vertebral case-level comparison were reviewed.
    RESULTS: One en bloc and two piecemeal resections were performed, with decompression and stabilization as indicated. Postoperatively, neurological status improved in all patients, although functional recovery varied. Cases 1 and 2 died of systemic disease progression 4 and 24 months after operation respectively. Case 3 was alive at the latest follow-up, 20 months after surgery. Five published reports of spinal involvement from MBC were identified, of which three met the criteria for vertebral case-level comparison.
    CONCLUSIONS: MBC with spinal metastasis is rare, and the clinical circumstances requiring spine-directed treatment vary considerably. Surgery may be considered for neurological compression or mechanical instability, with the extent of intervention individualized according to the clinical setting. Systemic therapy remains essential for metastatic disease control, and current evidence is insufficient to define an optimal surgical strategy or establish an independent survival benefit from surgery.
    Keywords:  Male breast cancer; Spinal instability; Spinal metastasis; Spine surgery; Vertebral metastasis
    DOI:  https://doi.org/10.1016/j.wneu.2026.125503
  7. Clin Transl Radiat Oncol. 2027 Jan;62 101336
       Purpose: Bone metastases from head and neck squamous cell carcinoma (HNSCC) are a rare clinical entity, with limited data guiding management. This study aimed to evaluate the oncological outcomes of stereotactic body radiotherapy (SBRT) for this rare condition.
    Methods: Patients who received SBRT for HNSCC-derived bone metastases between 2015 and 2024 were analyzed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. The cumulative incidence of local failures (LF) and post-SBRT fractures was analyzed with death as competing event. Adverse events were graded according to CTCAE v5.0.
    Results: Thirty-four patients with 54 irradiated bone metastases from 11 European centers were included. Median age was 63 years (range, 39-86); and the most common primary sites were the oropharynx (n = 12, 35.3%), nasopharynx (n = 8, 23.5%), and oral cavity (n = 5, 14.7%). The median prescribed biologically effective dose (BED10) was 60.0 Gy (IQR, 56.0-72.0 Gy). After a median follow-up of 23.3 months in patients alive at last contact, 2-year OS and PFS were 41.2% (95% CI, 24.3-57.3%) and 8.8% (95% CI, 2.3-21.1%), while the 2-year cumulative incidence of LF and fractures was 14.1% (95% CI, 3.0-27.8%) and 1.9% (95% CI, 0.0-6.9%). In exploratory analyses, patients treated for >1 bone metastases had inferior OS compared to those with a single treated bone metastasis (HR 2.58; 95% CI, 1.08-6.15; p = 0.033). Grade 3 adverse events occurred in one patient (2.9%), with no grade 4-5 events.
    Conclusion: Although PFS remained limited, SBRT was associated with high local control and a low observed rate of severe adverse events in patients with HNSCC-derived bone metastases. Prospective studies are warranted to validate these findings and optimize patient selection.
    Keywords:  Bone metastases; HNSCC; Head and neck squamous cell carcinoma; MDT; Metastasis-directed therapy; SBRT; Stereotactic body radiation treatment
    DOI:  https://doi.org/10.1016/j.ctro.2026.101336
  8. Cancers (Basel). 2026 Nov 04. pii: 3543. [Epub ahead of print]18(21):
      Long-term survivors of hormone receptor-positive breast cancer, prostate adenocarcinoma, and renal cell carcinoma may develop metastatic disease years after treatment. Vertebral involvement can cause instability and neurologic injury, but first late vertebral recurrence is poorly measured because studies frequently combine vertebral and other skeletal events. This narrative review synthesizes selected recurrence cohorts, experimental studies, randomized trials, and professional guidance. It distinguishes first late distant recurrence, biochemical recurrence, and progression of established metastatic disease; examines proposed mechanisms of marrow persistence; and considers detection and management. Late systemic risk is established, particularly in estrogen receptor-positive breast cancer, but vertebral-specific incidence remains uncertain. Niche studies provide biological plausibility without demonstrating a uniquely vertebral dormancy process. MRI assesses local marrow and neural involvement, while tumor-appropriate PET/CT maps disease distribution; tracer biology influences detection. Relevant trials address different questions: spinal MRI screening in metastatic castration-resistant prostate cancer, treatment of identified high-risk bone lesions, or metastasis-directed therapy in oligorecurrent disease. None establishes scheduled spine MRI for asymptomatic disease-free survivors. Concerning symptoms and tumor-specific recurrence signals warrant timely diagnostic evaluation. Identified lesions require assessment of neurologic compression, oncologic options, mechanical stability, and systemic status. Prospective cohorts and intervention studies should measure vertebral-specific events, function, quality of life, and downstream harms before risk-defined screening is recommended.
    Keywords:  cancer survivorship; late recurrence; narrative review; spinal cord compression; tumor dormancy; vertebral metastasis
    DOI:  https://doi.org/10.3390/cancers18213543
  9. J Bone Oncol. 2026 Dec;61 100811
      Tumor-associated bone metabolic disorders are increasingly recognized as major complications of cancer, contributing to skeletal fragility, pain, disability, and reduced quality of life. These disorders are biologically heterogeneous and should not be considered a single entity. Bone metastases, multiple myeloma and other marrow-involving malignancies, non-bone-metastatic solid tumors, and cancer therapy-related bone injury differ substantially in the degree of tumor-bone interaction, marrow niche remodeling, systemic inflammation, endocrine disturbance, and treatment exposure. In this review, we discuss tumor-associated skeletal dysfunction from three perspectives: direct tumor-induced bone remodeling, systemic host-mediated bone loss, and treatment-induced skeletal toxicity. Current evidence suggests that tumor-derived factors, metabolic stress, osteoimmune dysregulation, endocrine alterations, cachexia, sarcopenia, reduced mechanical loading, and osteocyte dysfunction collectively impair bone homeostasis. We highlight growing evidence that non-bone-metastatic tumors may affect the skeleton mainly through systemic mechanisms rather than direct bone invasion. We also distinguish established mechanisms from less clearly defined mechanisms across different tumor types and discuss challenges in biomarker development, mechanistic stratification, and personalized skeletal protection.
    Keywords:  Bone homeostasis; Cancer cachexia; Cancer treatment-induced bone loss; Osteoimmunology; Tumor-associated bone metabolic disorders
    DOI:  https://doi.org/10.1016/j.jbo.2026.100811
  10. Orthop Surg. 2026 Nov 11.
       OBJECTIVES: To compare Wiltse approach-based invasion-controlled surgery (ICS) with traditional open surgery (TOS) for symptomatic thoracolumbar spinal metastases within the Neurologic, Oncologic, Mechanical, and Systemic (NOMS) framework, focusing on perioperative burden, postoperative recovery, neurological outcomes, pain, and QLQ-BM22 domains.
    METHODS: This retrospective cohort study included 30 patients undergoing ICS and 60 patients undergoing TOS from January 25, 2019, to January 25, 2022. Perioperative, neurological, and patient-reported outcomes were compared, including operative burden, postoperative recovery, complications, ASIA grade, VAS score, and QLQ-BM22 domains. Continuous variables were assessed with Shapiro-Wilk tests and compared using two-sided Welch independent-samples t-tests; categorical variables were analyzed using Pearson's χ2 or exact tests, and Mann-Whitney U tests were used for sensitivity analyses when patient-level data were available.
    RESULTS: The groups differed in preoperative ASIA distribution (p = 0.036). Compared with TOS, ICS was associated with shorter operative time (p < 0.001), lower blood loss (p = 0.005), lower transfusion volume (p < 0.001), less postoperative drainage (p = 0.021), earlier ambulation (p < 0.001), and a shorter interval to subsequent oncologic treatment (p < 0.001). The day-1 leukocyte count was lower in the ICS group (p = 0.028), whereas C-reactive protein was higher (p = 0.042). The overall complication frequency (p = 1.000), postoperative-week-2 ASIA distribution (p = 0.247), and favorable neurological outcome frequency (53.3% vs. 50.0%, p = 0.766) did not differ significantly between groups.
    CONCLUSIONS: Wiltse approach-based ICS was associated with reduced operative burden and faster postoperative recovery, without evidence of a worse postoperative neurological distribution in the unadjusted comparison. ICS may be considered a complementary muscle-sparing option within NOMS-guided management for appropriately selected patients who require posterior stabilization with decompression or separation.
    TRIAL REGISTRATION: ClinicalTrials.gov identifier: ChiCTR1800016921.
    Keywords:  Wiltse approach; invasion‐controlled surgery; spinal metastases; traditional open surgery
    DOI:  https://doi.org/10.1111/os.70411
  11. Spine J. 2026 Nov 12. pii: S1529-9430(26)00750-3. [Epub ahead of print]
      Radiation from medical imaging is increasingly recognized as a modifiable carcinogenic exposure. The precise population-level cancer burden remains debated, but the oncologic cost is real, unevenly distributed by patient age and sex and largely controllable at the point of clinical decision-making. Spine care occupies a central position in this discussion because many patients are exposed to ionizing radiation repeatedly over the course of their care. This includes patients within a wide age range undergoing surgery, fluoroscopic- or computerized tomography (CT)-guided percutaneous interventions, and serial imaging. In younger patients, the attributable cancer risk per unit dose is greater and the latency period for radiation-induced malignancy is longer; in patients requiring repeated interventions, cumulative lifetime radiation exposure may also become substantial. These concerns are increasingly relevant as navigation, robotics, and augmented reality platforms have expanded the use of preoperative and intraoperative CT. In this context, we sought to synthesize the current evidence across radiation physics, carcinogenesis risk modeling, perioperative radiation sources, patient-level risk heterogeneity, surgeon and operating room personnel exposure, and technology-specific evidence. Particular attention is paid to patient-level heterogeneity as cancer risk per unit dose varies by nearly an order of magnitude across age and sex strata such that oncologic implications of an otherwise identical imaging protocol may differ substantially depending on the patient receiving it. Building on the evidence, we introduce a radiation budgeting framework that treats the full perioperative episode as the unit of radiation accountability and propose radiation stewardship in spine care as a structural analog to antibiotic stewardship in infectious disease.
    Keywords:  ALARA; Adolescent idiopathic scoliosis; Cancer risk; Intraoperative CT navigation; Linear no-threshold model; Occupational radiation; Radiation exposure; Radiation stewardship; Spine surgery
    DOI:  https://doi.org/10.1016/j.spinee.2026.11.011
  12. Eur Spine J. 2026 Nov 11.
       PURPOSE: Evidence on the optimal treatment of intramedullary spinal cord metastasis (ISCM) is limited. We pooled individual patient data (IPD) to compare survival after resection versus non-resection and identify prognostic factors.
    METHODS: A systematic review and IPD pooled analysis following PRISMA-IPD included 257 adult ISCM patients from 207 case reports and two institutional series. Primary outcome was overall survival; secondary outcomes were neurological status and complications. Multivariable Cox regression included sensitivity analyses for missing data, publication bias and immortal-time bias (landmark analyses); logistic regression evaluated discharge outcomes.
    RESULTS: Resection was performed in 152 patients (59.1%). Median survival was 14 weeks after resection vs. 6 weeks without (overall 11 weeks; log-rank p = 0.003). After adjustment, resection was associated with longer survival (HR 0.50, 95% CI 0.32-0.77, p = 0.002), robust to missing-data and publication-bias analyses but attenuated in landmark analyses (4 weeks: HR 0.89, 95% CI 0.51-1.57). Poor baseline neurological status (McCormick III - V: HR 3.68, p < 0.001), multiple lesions (HR 3.09, p < 0.001) and higher age (HR 1.02 per year, p = 0.024) predicted shorter survival. Resection was not associated with neurological improvement at discharge (OR 0.68, 95% CI 0.32-1.47, p = 0.331).
    CONCLUSION: Surgical resection of ISCM was independently associated with longer survival, although residual selection and immortal-time bias cannot be excluded. Baseline neurological status and lesion number were the dominant prognostic factors. Prospective multicentre studies are needed to define optimal treatment.
    Keywords:  Individual patient data meta-analysis; Intramedullary spinal cord metastasis; Prognostic factors; Radiotherapy; Surgical resection; Survival analysis
    DOI:  https://doi.org/10.1007/s00586-026-10503-4
  13. EJNMMI Res. 2026 Aug 11. pii: 156. [Epub ahead of print]16(1):
       BACKGROUND: Bone metastases frequently occur in advanced-stage malignancies, contributing to diminished quality of life and unfavorable prognoses. However, conventional imaging modalities for diagnosing bone metastases exhibit inherent limitations. This study aimed to evaluate the diagnostic utility of fibroblast activation protein inhibitor (FAPI) imaging using [99mTc]Tc-H7ND for detecting bone metastases (BM). From June 2021 to September 2023, 564 patients with malignancies underwent FAPI imaging were screened. Eighty patients with confirmed or suspected BM were included. FAPI SPECT/CT was compared with CT, MRI, bone scintigraphy (BS), and [¹⁸F]FDG PET/CT for diagnostic efficacy. The uptake values in different components of BM were assessed, alongside discussions on potential of FAPI imaging in evaluating treatment response.
    RESULTS: Eighty patients (median age: 60 years; range: 23-79 years; 48 men) with confirmed or suspected BM were included, of these, 64 were confirmed BM. FAPI SPECT/CT demonstrated superior sensitivity (96.5%) and accuracy (95.9%) compared to CT (59.7%, 67.1%; p < 0.001), detecting significantly more lesions than CT (p < 0.001) and MRI (p = 0.041). FAPI imaging outperformed BS in detecting osteolytic and mixed metastases, identifying 12 and 9 additional lesions, respectively. FAPI uptake differed significantly among BM subtypes, with median SUVmax values of 13.41 (osteolytic), 10.78 (mixed), and 2.70 (osteoblastic) (p < 0.001). Compared to conventional imaging combinations, FAPI identified new lesions in 46.3% of patients, prompting treatment modifications in 86.5% of cases. For patients who underwent follow-up FAPI imaging, changes in SUVmax of BM correlated with RECIST 1.1 criteria.
    CONCLUSION: The findings may enhance diagnostic performance in detecting BM across malignancies, particularly for osteolytic and mixed metastases. Preliminary observations also suggest possible applications in monitoring therapeutic response, though further validation is required to confirm these exploratory findings. This is a retrospective study, utilizing data collected from a registry (registration number: ChiCTR2100048093; date of registration: June 30, 2021).
    Keywords:  Bone metastases; Diagnostic efficiency; FAPI imaging; [99mTc]Tc-H7ND SPECT/CT
    DOI:  https://doi.org/10.1186/s13550-026-01502-z
  14. Transl Cancer Res. 2026 Oct 30. 15(10): 790
       Background and Objective: Bone metastasis is a common complication of advanced solid tumors and has been associated with poor efficacy of immune checkpoint inhibitors (ICIs). This review aims to summarize the clinical evidence linking bone metastasis to reduced ICI efficacy, to dissect the bone marrow microenvironment (BMM)-mediated mechanisms of immunotherapy resistance, and to evaluate current and emerging combination strategies.
    Methods: We searched PubMed, Embase, and Web of Science from database inception to August 2026 for studies on bone metastasis, immunotherapy, immune resistance, and combination therapy. Clinical evidence was graded from randomized controlled trials (RCTs) (level I) to preclinical (animal or in vitro) studies (level V).
    Key Content and Findings: Clinical studies consistently show lower response rates and shorter survival in patients with bone metastasis treated with ICIs, although most data are retrospective and unadjusted. Mechanistically, tumor cells exploit the immune-privileged hematopoietic stem cell (HSC) niche, hypoxia-driven metabolic reprogramming, immunosuppressive immune cell remodeling, and bone-immune crosstalk to evade immune attack. Combination strategies, including bone-targeted agents, radiotherapy, and anti-angiogenic therapy, show promise but are supported mainly by retrospective evidence; emerging approaches [nanomaterials, the sialic acid-Siglec axis, transforming growth factor-β (TGF-β) inhibition, and gut microbiota modulation] remain preclinical.
    Conclusions: Bone metastasis represents an organ-specific model of immunotherapy resistance. Mechanism-based combination strategies and bone-specific biomarkers are promising avenues to improve ICI efficacy, but high-level prospective evidence is urgently needed.
    Keywords:  Immunotherapy; bone marrow microenvironment (BMM); bone metastasis; combined immunotherapy; immunosuppression
    DOI:  https://doi.org/10.21037/tcr-2026-1860
  15. Front Oncol. 2026 ;16 1984003
      Cyclin-dependent kinases (CDKs) are established and emerging drug targets in cancer. Clinical success of CDK4/6 inhibitors in HR+/HER2- breast cancer has validated the CDK family therapeutically and stimulated development of both next-generation cell-cycle CDK inhibitors and inhibitors targeting transcriptional CDKs (CDK7-9, CDK11-13 and CDK19). Experience across these programs has shown that the therapeutic value of a CDK inhibitor is determined not only by kinase selectivity, but also by tumor dependency, compensatory pathways, normal-tissue biology, pharmacokinetic exposure and dosing schedule. Transcriptional CDKs are particularly attractive in cancers that depend on highly active oncogenic transcriptional programs, potentially creating a therapeutic window despite their essential roles in normal cells. In this review, we summarize CDKs as cancer drug targets with emphasis on transcriptional CDKs and metastatic disease. We specifically explore the potential of CDK9 inhibition in bone metastases, including effects on both tumor cell survival and RANKL-NF-κB -driven osteoclastogenic bone microenvironment, and discuss how CDK12 and CDK13 may provide complementary or context-dependent therapeutic opportunities.
    Keywords:  bone metastases; cyclin-dependent kinase; drug target; metastatic disease; transcriptional CDKs
    DOI:  https://doi.org/10.3389/fonc.2026.1984003